key: cord-0913690-10sh3697
authors: Wang, Ruoke; Zhang, Qi; Ge, Jiwan; Ren, Wenlin; Zhang, Rui; Lan, Jun; Ju, Bin; Su, Bin; Yu, Fengting; Chen, Peng; Liao, Huiyu; Feng, Yingmei; Li, Xuemei; Shi, Xuanling; Zhang, Zheng; Zhang, Fujie; Ding, Qiang; Zhang, Tong; Wang, Xinquan; Zhang, Linqi
title: Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
date: 2021-06-08
journal: Immunity
DOI: 10.1016/j.immuni.2021.06.003
sha: efe19ec7f3e66ae29c48d2159537fbeb4e532435
doc_id: 913690
cord_uid: 10sh3697

SARS-CoV-2 variants continue to emerge during the global pandemic and may facilitate escape from current antibody therapies and vaccine protection. Here, we showed that the South African variant B.1.351 was the most resistant to current monoclonal antibodies and convalescent plasma from COVID-19-infected individuals, followed by the Brazilian variant P.1 and the UK variant B.1.1.7. This resistance hierarchy corresponded with Y144del and 242-244del mutations in the N-terminal domain and K417N/T, E484K and N501Y mutations in the receptor binding domain (RBD) of SARS-CoV-2. Crystal structural analysis of B.1.351 triple mutant (417N-484K-501Y) RBD complexed with monoclonal antibody P2C-1F11 revealed the molecular basis for antibody neutralization and escape. B.1.351 and P.1 also acquired the ability to use mouse and mink ACE2 receptor for entry. Our results demonstrate major antigenic shifts and potential broadening of the host range for B.1.351 and P.1 variants, which pose serious challenges to our current antibody therapies and vaccine protection.

Introduction (Johnson, 2021; Novavax, 2021; Voysey et al., 2021; Xia et al., 2021) .

However, there is growing concern that the epidemic raging worldwide may be 87 generating new SARS-CoV-2 variants that are antigenically distinct from the 88 prototype strain, rendering current antibody and vaccine strategies ineffective 89 (Callaway, 2021) . P2C-1F11 revealed a molecular basis for antibody neutralization and escape. 137 We also show that mutations acquired by B.1.351 and P.1 substantially 138 improve their ability to use mouse and mink ACE2 for entry. These results epitope specificity ( Figure 1B ) (Barnes et al., 2020; Du et al., 2020; Ge et al., 152 REGN10987 and CB6) or being studied for clinical use (P2C-1F11, BD368-2, 184 S309, and P2B-1G5) were variably affected by pseudoviruses carrying these 185 mutations ( Figure 1C and Figure S1 ). The IC50 of REGN10933 dropped 13.0-186 and 8.2-fold against B.1.351 and P.1, respectively, largely due to the K417N/T 187 and E484K mutations ( Figure 1C ). Several mutations within the REGN10933 188 epitope, such as Y453F and F486L, were also associated with a substantial 189 reduction in neutralization. N439K, located in the REGN10987 epitope, 190 showed a 26.6-fold reduction in IC50. The most substantially impacted mAb 191 was CB6, one of the paired antibodies developed by Eli Lilly and approved for 192 EUA, for which the neutralization against B.1.351 and P.1 pseudoviruses was 193 below detection limit (BDL) when the highest concentration (1µg/mL) was used.

The reduction and loss of neutralization were largely attributed to K417N/T 195 ( Figure 1C ). Despite being a Class I or RBS-A antibody, P2C-1F11 was 196 virtually unaffected by the mutations, as were the Class III and IV anti-RBD 197 mAbs REGN10987, S309, and P2B-1G5 ( Figure 1C ).

Next, we studied the binding avidity of the 12 mAbs to the 28 mutant S proteins 200 expressed on cell surfaces. There was a strong correlation between 201 neutralization and binding avidity ( Figure 1D and Figure S2 ), indicating that 202 compromised binding avidity is a major escape mechanism. Lastly, soluble 203 human ACE2 showed improved binding to all three variants, as well as 204 pseudoviruses bearing single N501Y and triple K417N-E484K-N501Y 205 mutations ( Figure 1D , and Figure S2 ). This finding indicates that N501Y plays interactions with RBD-3M residues Y453, Q493, T500 and Y501 around the 241 501 position but had much less interaction with the wildtype RBD residue 242 asparagine (N) at the 501 ( Figure 2B and Similar to the wildtype RBD, P2C-1F11 did not directly bind to E484K in the 248 RBD-3M ( Figure 2B and Table S2 ). This explains why E484K had no 249 detectable impact on binding and neutralizing activity of P2C-1F11. However, 250 the E484K mutation resulted in the complete loss of BD368-2 and P5A-1B9 251 neutralization ( Figure 1C and Figure S1 ). Structural analysis showed that the respectively) ( Figure S3 ). Furthermore, antibodies that lost their neutralizing 264 activities including CB6, P5A-1D2, P5A-3C8, P22A-1D1, BD368-2, and 265 P5A-1B9 failed to show detectable levels of binding to the RBD-3M ( Figure S3 ).

These results indicate that antibody binding activity correlates well with 267 antibody neutralizing activities. contributed to such changes ( Figure 3C and Figure S4 ). In contrast, for pseudoviruses carrying only the K417N mutant, neutralization efficacy 309 invariably increased for all plasma sample studied, with an average 2.0-fold 310 improvement. A similar trend was also seen for pseudoviruses carrying only 311 the K417T mutant ( Figure 3C and Figure S4 ). 3C and Figure S4 ). This suggests that anti-NTD antibodies account for a major Enhanced entry of SARS-CoV-2 variants through mouse and mink ACE2.

To study the potential impact of SARS-CoV-2 variants on host range and 332 cross-species transmission, we characterized the ability of ACE2 from nine host species to support the entry of 28 SARS-CoV-2 mutant pseudoviruses.

HeLa cell lines stably expressing the ACE2 molecules were subjected to 335 infection. The entry efficiency was measured and presented as fold-change 336 relative to WT D614G. As shown in Figure concern about the potential spread of these new variants to mice and beyond. There are restrictions to the availability of convalescent plasma due to limited 606 stock. We will share these reagents until the stock runs out. Outpatients with [229] [230] [231] [232] [233] [234] [235] [236] [237] Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., 831 Yang, Y., et al. (2020) Diamond, M., Chen, R., Xie, X., Case, J., Zhang, X., VanBlargan, L., Liu, Y., Liu, J., Errico, 838 J., Winkler, E., et al. (2021) . SARS-CoV-2 variants show resistance to neutralization by 839 many monoclonal and serum-derived polyclonal antibodies. Res Sq. 840

Du, S., Cao, Y., Zhu, Q., Yu, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. 841 (2020) . Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely 842 Fujino, T., Nomoto, H., Kutsuna, S., Ujiie, M., Suzuki, T., Sato, R., Fujimoto, T., Kuroda, M., 850 Wakita, T., and Ohmagari, N. (2021) . Novel SARS-CoV-2 Variant Identified in Travelers 851 from Brazil to Japan. Emerging infectious diseases 27. 852

Ge, J., Wang, R., Ju, B., Zhang, Q., Sun, J., Chen, P., Zhang, S., Tian, Y., Shan, S., 853 Cheng, L., et al. (2021) . Antibody neutralization of SARS-CoV-2 through ACE2 receptor 854 mimicry. Nat Commun 12, 250. 855

Kreye, J., Reincke, S.M., Kornau, H.C., Sanchez-Sendin, E., Corman, V.M., Liu, H., Yuan, 888 M., Wu, N.C., Zhu, X., Lee, C.D., et al. (2020) Laffeber, C., de Koning, K., Kanaar, R., and Lebbink, J.H.G. (2021) . Experimental 894 evidence for enhanced receptor binding by rapidly spreading SARS-CoV-2 variants. 895 bioRxiv, 2021 .2002 .2022 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., 897 and Wang, X. (2020) . Structure of the SARS-CoV-2 spike receptor-binding domain bound 898 to the ACE2 receptor. Nature 581, 215-220. 899 Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., 900 Figueroa, A., et al. (2020) . Potent neutralizing antibodies against multiple epitopes on 901 SARS-CoV-2 spike. Nature 584, 450-456. 902 Liu, Y., Hu, G., Wang, Y., Ren, W., Zhao, X., Ji, F., Zhu, Y., Feng, F., Gong, M., Ju, X., et al. 903 (2021) . Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad 904 potential host range of SARS-CoV-2. Proc Natl Acad Sci U S A 118. 905

Maggi, F., Novazzi, F., Genoni, A., Baj, A., Spezia, P.G., Focosi, D., Zago, C., Colombo, A., 906 Cassani, G., Pasciuta, R., et al. (2021) . Imported SARS-COV-2 Variant P.1 Detected in 907

Traveler Returning from Brazil to Italy. Emerging infectious diseases 27. 908

McCallum, M., De Marco, A., Lempp, F.A., Tortorici, M.A., Pinto, D., Walls, A.C., 909 Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) B . 1 . 3 5 1 P . 1 L 1 8 F 6 9 -7 0 d e l Y 1 4 4 d e l A 2 2 2 V 2 4 2 -2 4 4 d e l K 4 1 7 N K 4 1 7 T N 4 3 9 K Y 4 5 3 F S 4 7 7 N T 4 7 8 I E 4 8 4 K F 4 8 6 L S 4 9 4 P N 5 0 1 Y 4 1 7 N / 4 8 4 K / 5 0 1 Y A 5 7 0 D E 5 8 3 D H 6 5 5 Y P 6 8 1 H T 7 1 6 I S 9 8 2 A D 1 1 1 8 H D 1 1 6 3 Y Fold changes in entry WT HeLa Human-ACE2 +1.0 -6.6 -1.0 -1.9 +1.5 +1.9 -1.6 -2.4 -3.4 -1.3 +1.2 -3.6 -2.0 -1.4 -3.2 -2.3 -1.5 -1.8 -3.6 -1.8 -2.0 -3.6 -1.3 -1.7 -10.6 -2.5 -1.1 -2.4 HeLa Erbat-ACE2 +1.0 -3.8 +1.3 -1.3 +2.4 +2.6 -1.0 -1.4 -5.8 -97.1 -38.4 -1.9 -4.0 -1.0 -3.1 -1.7 +2.0 -1.3 -1.4 -1.7 +1.1 -3.5 +1.6 -1.6 -16.5 -3.8 -1. 2 -2.3 HeLa Rsbat-ACE2 +1.0 -5.5 -37.8 -79 .4 +1.6 +1.8 -2.0 -1.9 -6.7 -2.1 -1.5 -3.4 -2.5 -1.3 -2.9 -8.8 -1.7 -1.5 -3.6 -195.8 -1.8 -3.3 +1.1 -1.7 -11.4 -2.4 -1.1 -2.7

HeLa Pangolin-ACE2 +1.0 -6.5 -1.2 -1.5 +1.8 +2.4 -2.0 -2.0 -2.6 -1.0 +1.3 -3.0 -1.8 -1.2 -2.3 -2.2 -1.1 -1.3 -2.6 -2.0 -1.9 -3.1 +1.3 -1.8 -9.8 -1.7 +1.1 -2.2 HeLa Pig-ACE2 +1.0 -8. HeLa Cat-ACE2 +1.0 -5.3 -1.1 -2.3 +1.0 +1.1 -3.7 -2.5 -1.9 +1.1 +1.1 -4.0 -2.7 -1.7 -3.1 -1.5 -1.5 -1.5 -3.3 -1.9 -2.5 -2.6 -1.2 -2.2 -11.0 -2.0 -1.1 -1.8

HeLa Dog-ACE2 +1.0 -6.1 -1.2 -2.4 +1.1 +1.1 -3.9 -2.9 -1.9 +1.1 +1.0 -4.7 -2.9 -2.0 -3.6 -1.6 -1.7 -1.6 -3.8 -2.8 -2.9 -2.6 -1.3 -2.3 -10.0 -1.8 -1.1 -1.9

HeLa Mink-ACE2 +1.0 -1.2 +10.0 +4.3 -1.3 +2.9 -11.3 -1.4 -4.9 -2.8 -14.5 +2.3 +21.9 +1.0 -3.8 +26.6 +31.7 +4.0 +3.5 +3.0 +1.8 -4.3 +1.7 -2.3 -11.3 -5.2 +1.1 -2.3

HeLa Mouse-ACE2 +1.0 +26.6 +108.0 +71.7 +1.6 +3.8 +1.5 -1.4 -12.7 +23.1 +32.0 -9.7 -3.5 -1.3 -2.4 +24.0 +2.6 +3.0 +41.5 +44.7 +2.1 -4.7 +1.2 -1.3 -17.3 -5.8 -1.0 -3.5

Variants NTD RBD SD1-2

Aquarium: an automatic data -processing and experiment information 803 management system for biological macromolecular crystallography beamlines

PHENIX: 807 building new software for automated crystallographic structure determination

Efficacy and Safety of the 811 mRNA-1273 SARS-CoV-2 Vaccine

SARS-CoV-2 814 neutralizing antibody structures inform therapeutic strategies

Fast-spreading COVID variant can elude immune responses

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Characterization and structural basis of a lethal mouse

Neutralizing and 952 protective human monoclonal antibodies recognizing the N-terminal domain of the 953 SARS-CoV-2 spike protein

Sixteen novel lineages of 956 SARS-CoV-2 in South Africa

Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 959 and its Receptor ACE2. bioRxiv

BNT162b vaccines protect rhesus 962 macaques from SARS-CoV-2

Evaluating the Effects of 965

SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

with Potent Protection against SARS-CoV-2

Antibody resistance of SARS-CoV-2 variants B.1

mRNA 980 vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

REGN-COV2, a Neutralizing Antibody Cocktail, in 983 Outpatients with Covid-19

D614G Spike Mutation

Increases SARS CoV-2 Susceptibility to Neutralization

Serum Neutralizing Activity 990 Elicited by mRNA-1273 Vaccine

A single dose of an adenovirus-vectored vaccine provides 993 protection against SARS-CoV-2 challenge

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine

1005 (2020b). A highly conserved cryptic epitope in the receptor binding domains of 1006 SARS-CoV-2 and SARS-CoV

Structural and Functional Analysis 1009 of the D614G SARS-CoV-2 Spike Protein Variant

Potent and protective IGHV3-53/3-66 public antibodies and their shared 1012 escape mutant on the spike of SARS-CoV-2. Nature communications

A pneumonia outbreak associated with a new coronavirus of 1015 probable bat origin

Potently neutralizing and protective 1018 human antibodies against SARS-CoV-2

C-Plasma16 +1.0 +1.1 BDL BDL +1.8 +1.7 -1.0 -2.5 +1.2 -1.0 BDL C-Plasma17 +1

Variants RBD

A Randomized Clinical Trial. JAMA 325, [632] [633] [634] [635] [636] [637] [638] [639] [640] [641] [642] [643] [644] Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, 861 Y., Koon, K., Patel, K., et al. (2020) . Studies in humanized mice and convalescent humans 862 yield a SARS-CoV-2 antibody cocktail. Science 369, 1010-1014. 863 Ho, D., Wang, P., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, 864 P., et al. (2021) .